Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Status:
Not yet recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether the addition of metronomic capecitabine
to the standard treatment can improve prognosis in locoregionally advanced head and neck
squamous cell carcinoma.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Hospital of Guangdong Medical University Fujian Medical University Union Hospital Guangzhou Panyu Central Hospital Hanzhong Central Hospital Jiangmen Central Hospital The Central Hospital of Yongzhou The First People's Hospital of Huaihua Yichang Central People's Hospital